Schroders Capital Global Innovation (INOV) has announced that its portfolio company Araris Biotech AG, has entered into an agreement to be acquired by Taiho Pharmaceutical Co. Ltd. for an upfront payment of US$400m, with the potential for additional milestone payments of up to US$740m. The transaction is expected to be completed in first half of 2025. … Continue reading Schroders Capital Global Innovation’s Araris Biotech sold to Taiho Pharmaceutical